FIELD: medicine.
SUBSTANCE: polypeptides include single-domain antibody against vWF, A1 domain of vWF, A1 domain of activated vWF, A3 domain of vWF, gp1b and/or collagen. Invention claims methods of obtaining indicated polypeptides, methods of coating devices applied in medical practice (e.g. in X-ray structural analysis, endoprosthetics) with indicated polypeptides.
EFFECT: obtainment of polypeptides for treatment of diseases requiring modulation of thrombocyte-mediated aggregation.
40 cl, 69 ex, 30 dwg, 32 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC POLYPEPTIDES, HOMOLOGUES THEREOF, FRAGMENTS THEREOF AND APPLICATION THEREOF FOR MODULATION OF PLATELET-MEDIATED AGGREGATION | 2004 |
|
RU2524129C2 |
| ISOLATED GLYCOPROTEIN IB ALPHA POLYPEPTIDE OF HUMAN THROMBOCYTES, FUSED PROTEIN, DNA MOLECULE (VERSIONS), EXPRESSION VECTOR (VERSIONS), CELL (VERSIONS), POLYPEPTIDE EXPRESSION METHOD, FUSED PROTEIN EXPRESSION METHOD, PHARMACEUTICAL COMPOSITION (VERSIONS), METHOD OF INHIBITING BODING OF BLOOD CELLS TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM, METHOD OF INHIBITING BONDING OF PROTEIN TO BIOLOGICAL TISSUE IN BIOLOGICAL SYSTEM AND DISORDER TREATMENT METHOD | 2004 |
|
RU2403262C2 |
| MONOVALENT CD40L-BINDING COMPOUNDS AND METHODS OF APPLICATION THEREOF | 2005 |
|
RU2364420C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| NANOBODIEC TM FOR TREATMENT OF AGGREGATION-MEDIATED DISEASES | 2006 |
|
RU2433139C2 |
| ANTIBODIES TO HPA-1a | 2015 |
|
RU2688627C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
| SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST TUMOUR NECROSIS FACTOR ALPHA, AND USE THEREOF | 2012 |
|
RU2704232C2 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
